tiprankstipranks
Trending News
More News >
Neurocrine (NBIX)
NASDAQ:NBIX
US Market
Advertisement

Neurocrine (NBIX) Stock Forecast & Price Target

Compare
1,444 Followers
See the Price Targets and Ratings of:

NBIX Analyst Ratings

Strong Buy
25Ratings
Strong Buy
21 Buy
4 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Neurocrine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$165.83
▲(28.64%Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $165.83 with a high forecast of $200.00 and a low forecast of $124.00. The average price target represents a 28.64% change from the last price of $128.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","129":"$129","153":"$153","177":"$177","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":165.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$165.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$124.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,129,153,177,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.91,134.37846153846152,139.84692307692308,145.3153846153846,150.78384615384616,156.25230769230768,161.72076923076924,167.18923076923076,172.65769230769232,178.12615384615384,183.5946153846154,189.06307692307692,194.53153846153845,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.91,131.75,134.59,137.43,140.27,143.11,145.95,148.79000000000002,151.63,154.47,157.31,160.15,162.99,{"y":165.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.91,128.53230769230768,128.15461538461537,127.77692307692307,127.39923076923077,127.02153846153846,126.64384615384616,126.26615384615384,125.88846153846154,125.51076923076923,125.13307692307693,124.75538461538461,124.37769230769231,{"y":124,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":153.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$200.00Average Price Target$165.83Lowest Price Target$124.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NBIX
TipRanks AITipRanks
Not Ranked
TipRanks
$145
Buy
12.48%
Upside
Reiterated
08/01/25
Neurocrine's overall score is driven by strong financial performance, robust earnings growth, and positive earnings call insights. While technical indicators present a mixed view, the company's high valuation and absence of dividends are key considerations. Continued attention to operational costs and external pricing pressures will be critical.
Evercore ISI Analyst forecast on NBIX
Cory KasimovEvercore ISI
Evercore ISI
$190$200
Buy
55.15%
Upside
Reiterated
07/31/25
Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)
H.C. Wainwright Analyst forecast on NBIX
Andrew FeinH.C. Wainwright
H.C. Wainwright
$168
Buy
30.32%
Upside
Reiterated
07/31/25
Buy Rating for Neurocrine's Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
William Blair Analyst forecast on NBIX
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
07/31/25
Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy RatingWe see potential investor concern surrounding Ingrezza’s sales outlook, particularly given its narrowing of 2025 sales guidance below its original upper-bound set earlier this year (see below). This is largely due to declining net price assumptions with heavier Part D contracting, but the upside here is that volume has increased with record number patient new starts on therapy being reported. Thus, the debate will now become if increased volumes, particularly in 2026, can overcome pricing pressures as Ingrezza looks to compete against Austedo, currently under the CMS Part D price negotiation procedure within the IRA. Crenessity revenue for the second quarter of $53.2 million significantly beat our estimate of $16.8 million as well as the consensus estimate of $24.0 million.
Guggenheim Analyst forecast on NBIX
Yatin SunejaGuggenheim
Guggenheim
$165$175
Buy
35.75%
Upside
Reiterated
07/31/25
Guggenheim Reaffirms Their Buy Rating on Neurocrine (NBIX)Guggenheim analyst Yatin Suneja raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $175.00 (from $165.00) while maintaining a Buy rating.
Needham Analyst forecast on NBIX
Ami FadiaNeedham
Needham
$139$161
Buy
24.89%
Upside
Reiterated
07/31/25
Neurocrine's Strong Financial Performance and Growth Prospects Drive Buy Rating
Truist Financial Analyst forecast on NBIX
Danielle BrillTruist Financial
Truist Financial
$163$165
Buy
28.00%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)
Leerink Partners Analyst forecast on NBIX
Marc GoodmanLeerink Partners
Leerink Partners
$160
Buy
24.12%
Upside
Reiterated
07/31/25
Neurocrine's Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
Wedbush
$137$141
Buy
9.38%
Upside
Reiterated
07/31/25
Neurocrine price target raised to $141 from $137 at WedbushNeurocrine price target raised to $141 from $137 at Wedbush
BMO Capital Analyst forecast on NBIX
Evan SeigermanBMO Capital
BMO Capital
$115$124
Hold
-3.81%
Downside
Reiterated
07/31/25
BMO Capital Sticks to Its Hold Rating for Neurocrine (NBIX)
Stifel Nicolaus Analyst forecast on NBIX
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$166$174
Buy
34.98%
Upside
Reiterated
07/31/25
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), GE Healthcare Technologies Inc (GEHC)
TD Cowen Analyst forecast on NBIX
Phil NadeauTD Cowen
TD Cowen
$165$170
Buy
31.87%
Upside
Reiterated
07/31/25
Neurocrine's Strong Growth Potential and Positive Outlook Justify Buy Rating
Morgan Stanley Analyst forecast on NBIX
Sean LaamanMorgan Stanley
Morgan Stanley
$150$158
Buy
22.57%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN) and Neurocrine (NASDAQ: NBIX)
Oppenheimer Analyst forecast on NBIX
Jay OlsonOppenheimer
Oppenheimer
$192
Buy
48.94%
Upside
Reiterated
07/31/25
Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)
Piper Sandler Analyst forecast on NBIX
David AmsellemPiper Sandler
Piper Sandler
$154$175
Buy
35.75%
Upside
Reiterated
07/31/25
Neurocrine price target raised to $175 from $154 at Piper SandlerNeurocrine price target raised to $175 from $154 at Piper Sandler
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NBIX
TipRanks AITipRanks
Not Ranked
TipRanks
$145
Buy
12.48%
Upside
Reiterated
08/01/25
Neurocrine's overall score is driven by strong financial performance, robust earnings growth, and positive earnings call insights. While technical indicators present a mixed view, the company's high valuation and absence of dividends are key considerations. Continued attention to operational costs and external pricing pressures will be critical.
Evercore ISI Analyst forecast on NBIX
Cory KasimovEvercore ISI
Evercore ISI
$190$200
Buy
55.15%
Upside
Reiterated
07/31/25
Evercore ISI Sticks to Their Buy Rating for Neurocrine (NBIX)
H.C. Wainwright Analyst forecast on NBIX
Andrew FeinH.C. Wainwright
H.C. Wainwright
$168
Buy
30.32%
Upside
Reiterated
07/31/25
Buy Rating for Neurocrine's Crenessity Driven by Strong Sales and Transformative Impact on CAH Treatment
William Blair Analyst forecast on NBIX
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
07/31/25
Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy RatingWe see potential investor concern surrounding Ingrezza’s sales outlook, particularly given its narrowing of 2025 sales guidance below its original upper-bound set earlier this year (see below). This is largely due to declining net price assumptions with heavier Part D contracting, but the upside here is that volume has increased with record number patient new starts on therapy being reported. Thus, the debate will now become if increased volumes, particularly in 2026, can overcome pricing pressures as Ingrezza looks to compete against Austedo, currently under the CMS Part D price negotiation procedure within the IRA. Crenessity revenue for the second quarter of $53.2 million significantly beat our estimate of $16.8 million as well as the consensus estimate of $24.0 million.
Guggenheim Analyst forecast on NBIX
Yatin SunejaGuggenheim
Guggenheim
$165$175
Buy
35.75%
Upside
Reiterated
07/31/25
Guggenheim Reaffirms Their Buy Rating on Neurocrine (NBIX)Guggenheim analyst Yatin Suneja raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $175.00 (from $165.00) while maintaining a Buy rating.
Needham Analyst forecast on NBIX
Ami FadiaNeedham
Needham
$139$161
Buy
24.89%
Upside
Reiterated
07/31/25
Neurocrine's Strong Financial Performance and Growth Prospects Drive Buy Rating
Truist Financial Analyst forecast on NBIX
Danielle BrillTruist Financial
Truist Financial
$163$165
Buy
28.00%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)
Leerink Partners Analyst forecast on NBIX
Marc GoodmanLeerink Partners
Leerink Partners
$160
Buy
24.12%
Upside
Reiterated
07/31/25
Neurocrine's Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
Wedbush
$137$141
Buy
9.38%
Upside
Reiterated
07/31/25
Neurocrine price target raised to $141 from $137 at WedbushNeurocrine price target raised to $141 from $137 at Wedbush
BMO Capital Analyst forecast on NBIX
Evan SeigermanBMO Capital
BMO Capital
$115$124
Hold
-3.81%
Downside
Reiterated
07/31/25
BMO Capital Sticks to Its Hold Rating for Neurocrine (NBIX)
Stifel Nicolaus Analyst forecast on NBIX
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$166$174
Buy
34.98%
Upside
Reiterated
07/31/25
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), GE Healthcare Technologies Inc (GEHC)
TD Cowen Analyst forecast on NBIX
Phil NadeauTD Cowen
TD Cowen
$165$170
Buy
31.87%
Upside
Reiterated
07/31/25
Neurocrine's Strong Growth Potential and Positive Outlook Justify Buy Rating
Morgan Stanley Analyst forecast on NBIX
Sean LaamanMorgan Stanley
Morgan Stanley
$150$158
Buy
22.57%
Upside
Reiterated
07/31/25
Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN) and Neurocrine (NASDAQ: NBIX)
Oppenheimer Analyst forecast on NBIX
Jay OlsonOppenheimer
Oppenheimer
$192
Buy
48.94%
Upside
Reiterated
07/31/25
Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)
Piper Sandler Analyst forecast on NBIX
David AmsellemPiper Sandler
Piper Sandler
$154$175
Buy
35.75%
Upside
Reiterated
07/31/25
Neurocrine price target raised to $175 from $154 at Piper SandlerNeurocrine price target raised to $175 from $154 at Piper Sandler
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

1 Month
xxx
Success Rate
15/24 ratings generated profit
63%
Average Return
+0.62%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +0.62% per trade.
3 Months
xxx
Success Rate
19/29 ratings generated profit
66%
Average Return
+2.03%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.52% of your transactions generating a profit, with an average return of +2.03% per trade.
1 Year
Phil NadeauTD Cowen
Success Rate
16/22 ratings generated profit
73%
Average Return
+7.30%
reiterated a buy rating 3 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +7.30% per trade.
2 Years
xxx
Success Rate
21/28 ratings generated profit
75%
Average Return
+12.09%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +12.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
17
19
19
10
2
Buy
21
23
22
50
36
Hold
8
6
5
7
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
48
46
67
42
In the current month, NBIX has received 38 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 165.83.
Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.56 with a range of $1.14 to $2.06. The previous quarter’s EPS was $1.06. NBIX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.12% of the time in the same period. In the last calendar year NBIX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for NBIX is $1.56 with a range of $1.14 to $2.06. The previous quarter’s EPS was $1.06. NBIX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.12% of the time in the same period. In the last calendar year NBIX has Preformed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $744.63M with a range of $709.40M to $788.24M. The previous quarter’s sales results were $687.50M. NBIX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.05% of the time in the same period. In the last calendar year NBIX has Preformed in-line its overall industry.
Next quarter’s sales forecast for NBIX is $744.63M with a range of $709.40M to $788.24M. The previous quarter’s sales results were $687.50M. NBIX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.05% of the time in the same period. In the last calendar year NBIX has Preformed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine’s 12-month average price target is 165.83.
    What is NBIX’s upside potential, based on the analysts’ average price target?
    Neurocrine has 28.64% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NBIX a Buy, Sell or Hold?
          Neurocrine has a consensus rating of Strong Buy which is based on 21 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Neurocrine’s price target?
            The average price target for Neurocrine is 165.83. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $200.00 ,the lowest forecast is $124.00. The average price target represents 28.64% Increase from the current price of $128.91.
              What do analysts say about Neurocrine?
              Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of NBIX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis